Condition:  Solid Tumor
Interventions:  Drug: S095029;  Drug: S95029 and Sym021;  Drug: S095029 and Sym021 and anti-HER2 therapy;  Drug: Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab
Sponsors:  Institut de Recherches Internationales Servier;  ADIR, a Servier Group company
**RECRUITING NOW**
Interventions:  Drug: S095029;  Drug: S95029 and Sym021;  Drug: S095029 and Sym021 and anti-HER2 therapy;  Drug: Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab
Sponsors:  Institut de Recherches Internationales Servier;  ADIR, a Servier Group company
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
